Introduction
Heart failure (HF) is a syndrome of symptoms (breathlessness, fatigue, oedema) caused by a structural or functional heart abnormality. Drug choice depends on the ejection fraction (EF): reduced (HFrEF ≤ 40%), mildly reduced (HFmrEF 41–49%) or preserved (HFpEF ≥ 50%).
HFrEF: the four pillars (ESC 2021/2023)
Four drug classes each reduce mortality and hospitalisation, and all four should be started early, within weeks, and titrated to target doses:
Symptom relief and other treatment
- Loop diuretics (furosemide) relieve congestion and oedema but do not improve survival: use the lowest dose that keeps the patient "dry".
- Ivabradine (sinus rhythm, heart rate ≥ 70 despite β-blocker), hydralazine + isosorbide dinitrate, digoxin (AF, symptoms), IV iron for iron deficiency, vericiguat.
- Devices: ICD (EF ≤ 35%), CRT (wide QRS).
- Treat the cause: ischaemia, hypertension, valves, arrhythmias; vaccinate against influenza and pneumococcus; salt and fluid advice, exercise rehabilitation.
HFmrEF and HFpEF
- SGLT2 inhibitors reduce hospitalisation; diuretics for congestion.
- Treat co-morbidities: hypertension, AF, diabetes, obesity, coronary disease.